Trade

with

Biomarin Pharmaceutical Inc
(NASDAQ: BMRN)
AdChoices
81.03
+6.02
+8.03%
After Hours :
81.03
0.00
0.00%

Open

75.73

Previous Close

75.01

Volume (Avg)

2.40M (1.14M)

Day's Range

75.40-81.83

52Wk Range

55.04-84.25

Market Cap.

11.92B

Dividend Rate ( Yield )

-

Beta

0.97

Shares Outstanding

147.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 548.48M

    • Net Income

    • -176.35M

    • Market Cap.

    • 11.92B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -29.76

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.97

    • Forward P/E

    • -117.65

    • Price/Sales

    • 18.55

    • Price/Book Value

    • 8.16

    • Price/Cash flow

    • -169.49

      • EBITDA

      • -118.79M

      • Return on Capital %

      • -9.46

      • Return on Equity %

      • -13.72

      • Return on Assets %

      • -9.46

      • Book Value/Share

      • 9.94

      • Shares Outstanding

      • 147.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 84.33

        • Credit Rating

        • BBB+

        • Analysts

        • 6

        • EPS Estimate

        • -0.77

        • Cashflow Estimate

        • -0.43

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 40.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 13.09

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 82.98

            • 82.75

            • Pre-Tax Margin

            • -27.75

            • 39.38

            • Net Profit Margin

            • -29.76

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 81.20

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -14.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -2.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.45

              • 0.76

              • Current Ratio

              • 7.32

              • 2.92

              • Quick Ratio

              • 5.75

              • 2.35

              • Interest Coverage

              • -5.58

              • 38.02

              • Leverage Ratio

              • 1.60

              • 2.21

              • Book Value/Share

              • 9.94

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -54.05

                • 217.39

                • P/E Ratio 5-Year High

                • -64.75

                • 634.30

                • P/E Ratio 5-Year Low

                • -11.69

                • 124.82

                • Price/Sales Ratio

                • 16.13

                • 9.52

                • Price/Book Value

                • 7.09

                • 8.61

                • Price/Cash Flow Ratio

                • -169.49

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -13.72

                    (0.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -9.46

                    (-0.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -9.31

                    (-1.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 0.64

                  • 1.48

                  • Asset Turnover

                  • 0.32

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -156.01M
                  Operating Margin
                  -28.44
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -169.49
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  52.80%

                  Mutual Fund Ownership

                  59.78%

                  Float

                  87.88%

                  5% / Insider Ownership

                  0.91%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    7,339,073

                  • 3.14

                  • 4.99

                  • VA CollegeAmerica AMCAP

                  •  

                    5,748,861

                  • 9.40

                  • 3.91

                  • Vanguard Capital Opportunity Fund

                  •  

                    4,769,100

                  • 0.00

                  • 3.24

                  • Vanguard Mid-Cap Index Fund

                  •  

                    2,516,851

                  • 1.92

                  • 1.71

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,390,376

                  • 0.95

                  • 1.62

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,328,644

                  • 0.00

                  • 1.58

                  • Fidelity® OTC Portfolio

                  •  

                    2,266,956

                  • 0.00

                  • 1.54

                  • iShares Nasdaq Biotechnology

                  •  

                    1,901,562

                  • -0.47

                  • 1.34

                  • Prudential Jennison Health Sciences

                  •  

                    1,752,708

                  • 0.00

                  • 1.19

                  • VA CollegeAmerica New Economy

                  •  

                    1,752,550

                  • 9.81

                  • 1.19

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Capital Research Global Investors

                  •  

                    17,876,013

                  • +0.55%

                  • 12.15

                  • Sands Capital Management, LLC

                  •  

                    11,925,248

                  • +22.47%

                  • 8.11

                  • Fidelity Management and Research Company

                  •  

                    8,262,792

                  • +31.43%

                  • 5.62

                  • Vanguard Group, Inc.

                  •  

                    8,226,701

                  • +2.44%

                  • 5.59

                  • PRIMECAP Management Company

                  •  

                    8,064,219

                  • -1.22%

                  • 5.48

                  • Jennison Associates LLC

                  •  

                    5,347,735

                  • -33.32%

                  • 3.64

                  • State Street Corp

                  •  

                    4,318,081

                  • +10.95%

                  • 2.94

                  • BlackRock Fund Advisors

                  •  

                    3,915,314

                  • +1.30%

                  • 2.66

                  • Wells Capital Management Inc.

                  •  

                    2,477,831

                  • -16.62%

                  • 1.68

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Mid Growth

                  Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product ...morecandidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, a...moren enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.lessless

                  Key People

                  Jean-Jacques Bienaime

                  CEO/Director

                  Pierre Lapalme

                  Chairman of the Board/Director

                  Mr. Daniel K. Spiegelman

                  CFO/Executive VP

                  Dr. Robert A. Baffi,PhD

                  Executive VP, Divisional

                  Jeff Ajer

                  Other Corporate Officer/Executive VP

                  • Biomarin Pharmaceutical Inc

                  • 770 Lindaro Street

                  • San Rafael, CA 94901

                  • USA.Map

                  • Phone: +1 415 506-6700

                  • Fax: +1 415 382-7889

                  • bmrn.com

                  Incorporated

                  1996

                  Employees

                  1,341

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: